Compile Data Set for Download or QSAR
maximum 50k data
Found 27 Enz. Inhib. hit(s) with all data for entry = 6890
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156371(US9018371, 12)
Affinity DataKi:  1.5nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156362(US9018371, 2)
Affinity DataKi:  1.66nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156373(US9018371, 14)
Affinity DataKi:  2.5nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156369(US9018371, 10)
Affinity DataKi:  3.69nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156364(US9018371, 4)
Affinity DataKi:  4.16nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156372(US9018371, 13)
Affinity DataKi:  6.80nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156370(US9018371, 11)
Affinity DataKi:  7.30nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156361(US9018371, 1)
Affinity DataKi:  7.40nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156363(US9018371, 3)
Affinity DataKi:  8.99nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156366(US9018371, 6)
Affinity DataKi:  12.7nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156374(US9018371, 15)
Affinity DataKi:  13nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156367(US9018371, 7)
Affinity DataKi:  19.9nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156368(US9018371, 8)
Affinity DataKi:  24.8nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156365(US9018371, 5)
Affinity DataKi:  25.8nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156375(US9018371, 16)
Affinity DataKi:  42.9nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156373(US9018371, 14)
Affinity DataKi:  230nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156364(US9018371, 4)
Affinity DataKi:  341nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156372(US9018371, 13)
Affinity DataKi:  420nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156371(US9018371, 12)
Affinity DataKi:  440nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A1(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156373(US9018371, 14)
Affinity DataKi:  530nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A1(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156372(US9018371, 13)
Affinity DataKi:  790nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A1(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156371(US9018371, 12)
Affinity DataKi:  860nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156370(US9018371, 11)
Affinity DataKi:  1.26E+3nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A1(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156370(US9018371, 11)
Affinity DataKi:  1.43E+3nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156365(US9018371, 5)
Affinity DataKi:  1.60E+3nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A1(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156364(US9018371, 4)
Affinity DataKi:  2.49E+3nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAdenosine receptor A2a(Homo sapiens (Human))
Fm Therapeutics

US Patent
LigandPNGBDBM156366(US9018371, 6)
Affinity DataKi:  4.02E+3nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
In DepthDetails US Patent